Prevention of Cardiovascular Disease in Women (2nd edition)

Objectives

Provide an evidence-based Malaysian clinical practice guideline for preventing, detecting, investigating and managing cardiovascular disease (CVD) in women of all ages, replacing the 2008 guideline and addressing women’s higher burden of adverse outcomes, including acute coronary syndrome mortality.[1][2]The framework seeks to correct the misconception that CVD predominantly affects men, strengthen awareness among health professionals and the public, and improve gender-sensitive primary and secondary prevention, diagnosis and treatment.[2][3]

• Increase awareness of women’s CVD risk, with all women aged over 40 encouraged to know their global risk and earlier assessment for those with established risk factors or a family history of premature CVD.[4][5][6]
• Identify high-risk women through assessment of symptoms, clinical and family history, smoking, physical activity, anthropometry, blood pressure, blood glucose and lipid profile, using risk classification and the Framingham general CVD risk score in primary care.[4][5][6]
• Reduce modifiable risks, including hypertension, dyslipidaemia, diabetes and pre-diabetes, abdominal obesity, smoking, poor diet, low physical activity, psychosocial factors and alcohol consumption.[5][6]
• Apply intensive lifestyle and appropriate pharmacological risk-factor reduction for women at high risk or with established CVD, combine lifestyle and medicine-based management when women at intermediate risk do not meet targets, and maintain healthy lifestyles among women at optimal risk.[7][6]
• Recognise sex-specific presentations and conditions, including atypical acute coronary syndrome symptoms, non-obstructive coronary heart disease, coronary microvascular dysfunction, Takotsubo cardiomyopathy, spontaneous coronary artery dissection, pregnancy-related risks, hormonal therapy considerations and treatment-related cardiotoxicity.[3][8][9][10][11][12]
• Promote healthy diets, physical activity, weight management and smoking cessation as the foundation of prevention, with nutritional support tailored to dyslipidaemia, hypertension, diabetes and obesity.[13][14][15]
• Achieve clinical targets for lipids, blood pressure and glycaemia according to age, CVD risk and comorbidity, while individualising treatment and accounting for pregnancy, breastfeeding and sex-specific adverse-effect risks.[16][17][18]

Implementation

Implement the guideline as a clinical reference for healthcare providers, with individual patient management determined by clinical presentation, professional judgement and locally available options.[1]Delivery is centred on routine preventive assessment in government clinics, integrated with gynaecological and breast examinations, supported by specialist investigation and treatment where required.[5]The source does not specify a dedicated implementation budget or wider resource-mobilisation plan; it notes that government-clinic risk assessment is available for a nominal but unspecified fee.[5]

• Use a multidisciplinary evidence-development process involving cardiologists, endocrinologists, general physicians and other specialists from government, private and university settings, supported by the Ministry of Health Malaysia Health Technology Assessment Unit secretariat and reviewed by national and international experts.[1][19][2]
• Base recommendations on Malaysian data where available and on systematic searches of PubMed and the Cochrane Database of Systematic Reviews, supplemented by international guidance and expert appraisal.[1][2]
• Provide risk assessment through history-taking, examination and laboratory investigation; use Framingham risk estimation while recognising that no Malaysian population-specific risk model was available and that other models may have limitations in local women.[5][20]
• Deliver lifestyle support through culturally appropriate nutrition advice, physical-activity promotion, weight-management interventions, smoking cessation and dietitian involvement where appropriate.[13][14]
• Investigate symptomatic women with clinical examination, electrocardiography, risk-factor screening and appropriately selected stress imaging, computed tomography, magnetic resonance imaging or invasive angiography, recognising sex-related differences in test performance and non-obstructive disease.[21][22][23][24]
• Coordinate specialist care for complex risks and conditions, including cardiotoxic cancer treatment, connective-tissue disease, human immunodeficiency virus, obstructive sleep apnoea, atrial fibrillation, stroke, peripheral arterial disease and pregnancy-related CVD risk.[25][26][27][28][29][12]
• Strengthen implementation through public awareness, continuing medical education and training on risk assessment and prevention, and clinical audits conducted by hospitals, units and general practices.[30]
• Document CVD risk, height, weight, waist circumference, body mass index, blood pressure, lipid results, fasting glucose and glycated haemoglobin in medical records; audit compliance periodically and target documentation in more than 70% of records.[7][31][12]
• Monitor treatment against specified lipid, blood-pressure and glycaemic targets, alongside clinical follow-up for higher-risk groups such as women with polycystic ovary syndrome, gestational diabetes, pregnancy-induced hypertension or pre-eclampsia.[16][32][33][34]
• Review the guideline at least every five years, or earlier where important new evidence becomes available.[1][30]

Monitoring & Evaluation

The guideline combines evidence review, clinical risk stratification, patient-record documentation, audits and periodic revision, but does not establish a unified national monitoring, reporting, surveillance or accountability framework.[1][30][31]

• Review the guideline in 2021 or earlier if important evidence emerges, and revise it at least every five years to reflect developments in women’s health.[1][30]
• Base recommendations on literature searches of PubMed and the Cochrane Database of Systematic Reviews for evidence published from 2008 to 30 August 2015, supplemented by reference searches, expert input and international guidance.[2]
• Grade recommendations from Grade I, supported by evidence or general agreement, to Grade III, where an intervention is not useful, ineffective or potentially harmful; classify evidence from Level A, based on multiple randomised trials or meta-analyses, to Level C, based on consensus, case studies or standard care.[30]
• Assess women’s cardiovascular disease risk through clinical history, examination, smoking and physical-activity status, blood pressure, anthropometry, glucose and lipid testing, using risk-classification tables and the Framingham Risk Score.[4][6]
• Document cardiovascular risk, height, weight, waist circumference, body mass index, blood pressure, lipid values, fasting glucose and glycated haemoglobin in medical records.[4][7]
• Conduct periodic clinical audits of compliance with guideline recommendations in hospitals, units and general practices.[4][30]
• Measure documentation and treatment performance through clinic-session numerators and denominators, including risk-score and anthropometric recording and achievement of blood-pressure, lipid and glycaemic targets.[31]
• Target documentation of the specified data in more than 70% of medical records, using the Audit of Clinical Diabetes, or Green Book, and associated cardiovascular and diabetes documentation arrangements.[31][12]
• Monitor body mass index and waist circumference at each visit, particularly for women with polycystic ovary syndrome, alongside blood pressure at every visit and periodic lipid and glucose-tolerance testing.[35][33]
• Use clinical treatment indicators including low-density lipoprotein cholesterol, blood pressure, fasting or pre-prandial glucose, post-prandial glucose, glycated haemoglobin, high-density lipoprotein cholesterol and triglycerides.[16][18]
• Apply risk- and age-specific targets, including low-density lipoprotein cholesterol below 2.6 mmol/L for established coronary heart disease or equivalents, below 1.8 mmol/L for diabetes with cardiovascular disease, and blood pressure below 140/90 mmHg for most women under 80 years.[15][17]
• Use the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome Registry as an evidence source on patient characteristics, treatments, interventions and in-hospital mortality, while National Health and Morbidity Survey data provide population surveillance of hypercholesterolaemia, hypertension, overweight and obesity.[36][37][38][39]
• Recognise a local evidence gap: no cardiovascular risk model based on the Malaysian population was available in the supplied material, although the Framingham score had retrospective validation in a multi-ethnic local population.[5][20]
• Undertake risk-stratified surveillance for selected clinical conditions, including serial ultrasound imaging for aortic aneurysms and echocardiography with strain, cardiac troponin and optional electrocardiography for chemotherapy-related cardiotoxicity.[40][12]

Beyond these clinical measures, audits, evidence standards and revision arrangements, the source does not specify national reporting lines, a consolidated indicator framework, evaluation responsibilities, sanctions or other formal accountability mechanisms.[4][30][31]

Costing & Financing

No implementation budget, costed plan, financing allocation, resource-mobilisation strategy, funding gap or economic assumption is specified for the guideline.[1][6][31]

• Offer cardiovascular risk assessment through government clinics for a nominal fee, although no amount, tariff or currency is provided.[5]
• Identify poor adherence as a source of substantial health-system costs from preventable cardiovascular events, without quantifying those costs or specifying funding for adherence interventions.[31]
• Record support for the guideline through an unrestricted educational grant from AstraZeneca to the National Heart Association of Malaysia; the funding statement indicates that the funder did not influence the guideline content.[41]

The source identifies resource-relevant service inputs, including government-clinic risk assessment, dietitian support, clinical audits, diagnostic testing and specialist monitoring, but does not assign costs, funding sources or budgets to these activities.[5][14][12]